权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

VesiVax Vaccine Formulation Against Neisseria gonorrhoeae

针对淋病奈瑟氏菌的 VesiVax 疫苗配方

基本信息

批准号：
10385208
负责人：
Gary Fujii
金额：
$ 29.98万
依托单位：
MOLECULAR EXPRESS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-18 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10385208
关键词：
Adjuvant Agonist Agreement Animals Antibiotic Resistance Antibodies Antigen Targeting Antigens Binding Proteins Case-Control Studies Development Diagnosis Double-Stranded RNA Evaluation Formulation Goals Gold Gonorrhea HIV Homologous Gene Hydrophobicity IgG1 Immune response Immunity Immunoglobulin A Immunoglobulin M Immunologics Individual Infection Interleukin-12 Knowledge Laboratories Lead Ligands Link Lipid A Lipid Bilayers Lipids Liposomes Membrane Modeling Molecular Molecular Conformation Mus Nature Neisseria gonorrhoeae Neisseria meningitidis Peptides Phase Preparation Prevention Procedures Process Protein Engineering Proteins Public Health Recombinant Proteins Recombinants Reproductive Tract Infections Research Risk Serogroup B Neisseria meningitidis Services Sexually Transmitted Diseases Small Business Innovation Research Grant Surface System TLR4 gene Technology Testing United States Universities Vaccinated Vaccines Vesicle Virus Diseases Women&apos s Group amphiphilicity bactericide base design dosage epidemiologic data flexibility gonorrhea vaccine immunogenicity lead candidate liposomal delivery mouse model nanoparticulate novel phase 2 study professor protective effect public health relevance reproductive tract vaccine access vaccine efficacy vaccine formulation vaccine immunogenicity viral transmission

项目摘要

Project Summary The principal goal of this project is to develop a VesiVax®-based vaccine against Neisseria gonorrhoeae (Ng). The studies proposed in this SBIR Phase I application will be focused on co-formulating an newly identified surface-displayed outer membrane Ng protein, MtrE, with various immunostimulatory adjuvant molecules (IAMs) in the VesiVax® liposomal platform. We will characterize the immunogenicity of these VesiVax®-MtrE-IAM formulations in mice, and select for the best candidates to be further evaluated in a novel mouse upper reproductive tract Ng infection model. These studies will elucidate the immunological profile in a vaccine that will correlate with protective immunity against Ng.

项目摘要该项目的主要目标是开发一种基于VesiVax®的抗奈瑟菌疫苗淋病（Ng）。SBIR第一阶段申请中提出的研究将重点关注共同制定新鉴定的表面展示外膜Ng蛋白，MtrE，与各种免疫刺激佐剂在VesiVax®脂质体平台中的IAM分子。我们将描述这些疫苗的免疫原性， VesiVax®-MtrE-IAM制剂，并选择最佳候选物，以在新的小鼠上生殖道Ng感染模型。这些研究将阐明免疫概况，疫苗将与针对Ng的保护性免疫相关。